{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:07:48Z","timestamp":1770476868413,"version":"3.49.0"},"reference-count":32,"publisher":"Frontline Medical Communications, Inc.","issue":"4","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cutaneous Medicine and Surgery"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1053\/sder.2001.29062","type":"journal-article","created":{"date-parts":[[2007,1,9]],"date-time":"2007-01-09T19:17:37Z","timestamp":1168370257000},"page":"260-267","source":"Crossref","is-referenced-by-count":21,"title":["Pimecrolimus cream 1%: A new development in nonsteroid topical treatment of inflammatory skin diseases"],"prefix":"10.12788","volume":"20","author":[{"given":"Adelaide A.","family":"Hebert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristyn Anne","family":"Warken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Cherill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","reference":[{"key":"10.1053\/sder.2001.29062_bib1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJM199912093412407","article-title":"Mechanisms of disease: Inflammatory skin diseases, T cells, and immune surveillance","volume":"341","author":"Robert","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/sder.2001.29062_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/13543784.9.1.69","article-title":"Ascomycins: Promising agents for the treatment of inflammatory skin diseases","volume":"9","author":"Paul","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/sder.2001.29062_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mjd.2000.107773","article-title":"The prevalence of atopic dermatitis in Oregon schoolchildren","volume":"43","author":"Laughter","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/sder.2001.29062_bib4","first-page":"3","article-title":"Natural history and clinical manifestations of atopic dermatitis","volume":"4","author":"Rajka","year":"1986","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1053\/sder.2001.29062_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0190-9622(99)70410-X","article-title":"Biochemical and immunologic mechanisms in atopic dermatitis: New targets for emerging therapies","volume":"41","author":"Hanifin","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/sder.2001.29062_bib6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1067\/mai.2000.106484","article-title":"Atopic dermatitis: New insights and opportunities for therapeutic intervention","volume":"105","author":"Leung","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/sder.2001.29062_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1034\/j.1600-0536.2001.440508.x","article-title":"Occupational contact dermatfus in nurses with hand eczema","volume":"44","author":"Strauss","year":"2001","journal-title":"Contact Dermatitis"},{"key":"10.1053\/sder.2001.29062_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1034\/j.1600-0536.2001.044003166.x","article-title":"Incidence of work-related hand eczema during apprenticeship: First results of a prospective cohort study in the car industry","volume":"44","author":"Funke","year":"2001","journal-title":"Contact Dermatitis"},{"key":"10.1053\/sder.2001.29062_bib9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/ije\/22.2.288","article-title":"Prevalence of hand dermatitis in different occupations","volume":"22","author":"Smit","year":"1993","journal-title":"Int J Epidemiol"},{"key":"10.1053\/sder.2001.29062_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s004200050243","article-title":"Risk for hand eczema in employces with past or present atopic dermatitis","volume":"71","author":"Coenraads","year":"1998","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1053\/sder.2001.29062_bib11","first-page":"509","article-title":"Hand eczema An evaluation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis","volume":"68","author":"Svensson","year":"1988","journal-title":"Acta Derm Venercol"},{"key":"10.1053\/sder.2001.29062_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1034\/j.1600-0536.2000.043006327.x","article-title":"Hand eczema in metalworker trainees\u2014an analysis of risk factors","volume":"43","author":"Berndt","year":"2000","journal-title":"Contact Dermatitis"},{"key":"10.1053\/sder.2001.29062_bib13","first-page":"422","article-title":"Management of hand dermatitis","volume":"20","author":"Woolner","year":"1994","journal-title":"Compr Ther"},{"key":"10.1053\/sder.2001.29062_bib14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1365-2133.1999.02819.x","article-title":"Long-term, intermittent treatment of chronic hand eczema with mometasone furoate","volume":"140","author":"Veien","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1053\/sder.2001.29062_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(84)80086-9","article-title":"Hand dermatitis: Practical management and current concepts","volume":"10","author":"Epstein","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/sder.2001.29062_bib16","first-page":"664","article-title":"Alterations in water content of the stratum corneum following long-term topical corticosteroids","volume":"90","author":"Sheu","year":"1991","journal-title":"J Formos Med Assoc"},{"key":"10.1053\/sder.2001.29062_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ajcd.2000.7184","article-title":"Efficacy of a skin-protective foam in the treatment of chronic hand dermatitis","volume":"11","author":"Fowler","year":"2000","journal-title":"Am J Contact Dermat"},{"key":"10.1053\/sder.2001.29062_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1081-1206(10)63003-7","volume":"79","author":"Leung","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1053\/sder.2001.29062_bib19","first-page":"144","article-title":"New concepts in atopic dermatitis","volume":"22","author":"Boguniewicz","year":"1996","journal-title":"Compr Ther"},{"key":"10.1053\/sder.2001.29062_bib20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2133.1997.tb03788.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology","volume":"137","author":"Meingassner","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1053\/sder.2001.29062_bib21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1365-2133.1998.02554.x","article-title":"The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion","volume":"139","author":"Mrowietz","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1053\/sder.2001.29062_bib22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archderm.134.7.805","article-title":"Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis","volume":"134","author":"Van Leent","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1053\/sder.2001.29062_bib23","series-title":"Abstract presented at 59th Annual Meeting of the American Academy of Dermatology","article-title":"Low blood concentrations of SDZ ASM 981 in infants with extensive atopic dermatitis treated with cream 1%","author":"Wahn","year":"2001"},{"key":"10.1053\/sder.2001.29062_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"key":"10.1053\/sder.2001.29062_bib25","series-title":"Abstract presented at 59th Annual Meeting of the American Academy of Dermatology","article-title":"Oral SDZ ASM 981: Pharmacokinetic profile in humans","author":"Greig","year":"2001"},{"key":"10.1053\/sder.2001.29062_bib26","series-title":"Abstract presented at 59th Annual Meeting of the American Academy of Dermatology","article-title":"Oral SDZ ASM 981: Clinical safety, tolerability, and efficacy in patients with moderate to severe chronic plaque psoriasis","author":"Greig","year":"2001"},{"key":"10.1053\/sder.2001.29062_bib27","doi-asserted-by":"crossref","unstructured":"Eichenfield L, Lucky A, Boguniewicz M, et al for the ASM 981 Cream 1% Multicenter Study Group: Safety and efficacy of ASM 981 (pimecrolimus) cream 1% in the treatment of atopic dermatitis in children and adolescents. J Am Acad Dermatol 2001 (submitted) (in press).","DOI":"10.1067\/mjd.2002.122187"},{"key":"10.1053\/sder.2001.29062_bib28","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545771.005","article-title":"The natural history of atopic dermatitis","author":"Williams","year":"2000"},{"key":"10.1053\/sder.2001.29062_bib29","series-title":"World Congress of Pediatric Dermatology","article-title":"Pimecrolimus (Eliel\u00ae, SDZ ASM 981) cream 1% is effective and safe in infants aged 3\u201323 months with atopic dermatitis","author":"Papp","year":"2001"},{"key":"10.1053\/sder.2001.29062_bib30","series-title":"Poster presented at 59th Annual Meeting of the American Academy of Dermatology","article-title":"Long-term management with SDZ ASM 981 cream 1% of atopic dermatitis in pediatric patients","author":"de Prost","year":"2001"},{"issue":"suppl 1","key":"10.1053\/sder.2001.29062_bib31","first-page":"P128","article-title":"1% SDZ ASM 981 cream effective in the treatment of chronic irritant hand dermatitis: A 6-week, randomized, double-blind, vehicle-controlled, single-center study","volume":"14","author":"Cherill","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1053\/sder.2001.29062_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2133.2001.04076.x","article-title":"The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study","volume":"144","author":"Queille-Roussel","year":"2001","journal-title":"Br J Dermatol"}],"container-title":["Seminars in Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S108556290180016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S108556290180016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scmsjournal.com\/wp-content\/uploads\/2016\/08\/v20i4-Hebert.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T15:08:31Z","timestamp":1616166511000},"score":1,"resource":{"primary":{"URL":"http:\/\/scmsjournal.com\/article\/buy_now\/?id=612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S108556290180016X"],"URL":"https:\/\/doi.org\/10.1053\/sder.2001.29062","relation":{},"ISSN":["1085-5629"],"issn-type":[{"value":"1085-5629","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}